Head-to-head evidence
Topiramate (Qudexy XR) vs Topiramate (Trokendi XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline
Topiramate (Qudexy XR)
Marketed by Upsher-Smith Laboratories, LLC
NCT00236717 · Phase 3 · completed
Patients were randomly assigned and the study was double-blinded, comparing topiramate against standard epilepsy medicines in a large group of newly diagnosed patients, using time to first seizure -- a direct clinical outcome -- as the primary measure. However, no results have been reported for this trial, so its actual effect on seizure control cannot be assessed from this record.
Topiramate (Trokendi XR)
Marketed by Supernus Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Qudexy XR)'s landscape · Topiramate (Trokendi XR)'s landscape